ES3061585T3 - Prophylaxis and treatment of angioedema - Google Patents

Prophylaxis and treatment of angioedema

Info

Publication number
ES3061585T3
ES3061585T3 ES21805547T ES21805547T ES3061585T3 ES 3061585 T3 ES3061585 T3 ES 3061585T3 ES 21805547 T ES21805547 T ES 21805547T ES 21805547 T ES21805547 T ES 21805547T ES 3061585 T3 ES3061585 T3 ES 3061585T3
Authority
ES
Spain
Prior art keywords
compound
solvate
pharmaceutically acceptable
acceptable salt
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES21805547T
Other languages
English (en)
Spanish (es)
Inventor
Anne Lesage
Peng Lu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharvaris GmbH
Original Assignee
Pharvaris GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharvaris GmbH filed Critical Pharvaris GmbH
Application granted granted Critical
Publication of ES3061585T3 publication Critical patent/ES3061585T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES21805547T 2020-11-12 2021-11-12 Prophylaxis and treatment of angioedema Active ES3061585T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20207273 2020-11-12
PCT/EP2021/081493 WO2022101395A1 (en) 2020-11-12 2021-11-12 Prophylaxis and treatment of angioedema

Publications (1)

Publication Number Publication Date
ES3061585T3 true ES3061585T3 (en) 2026-04-06

Family

ID=73401436

Family Applications (1)

Application Number Title Priority Date Filing Date
ES21805547T Active ES3061585T3 (en) 2020-11-12 2021-11-12 Prophylaxis and treatment of angioedema

Country Status (12)

Country Link
US (1) US20230338358A1 (https=)
EP (1) EP4243824B1 (https=)
JP (1) JP2023549849A (https=)
KR (1) KR20230107269A (https=)
CN (1) CN116685353A (https=)
AU (1) AU2021376885A1 (https=)
CA (1) CA3198246A1 (https=)
ES (1) ES3061585T3 (https=)
IL (1) IL302887A (https=)
MX (1) MX2023005563A (https=)
WO (1) WO2022101395A1 (https=)
ZA (1) ZA202305122B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3062067T3 (en) * 2022-03-25 2026-04-08 Pharvaris Gmbh Solid composition comprising solubilised bradykinin b2-receptor antagonists
TW202345810A (zh) * 2022-03-25 2023-12-01 瑞士商帕法瑞斯有限責任公司 包含緩激肽b2受體拮抗劑之固態延長釋放組成物
WO2025037920A1 (ko) 2023-08-16 2025-02-20 주식회사 엘지화학 수지 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005053660A2 (en) * 2003-12-03 2005-06-16 Lifecycle Pharma A/S Pharmaceutical compositions comprising danazol
US7816383B1 (en) * 2009-12-04 2010-10-19 Intermune, Inc. Methods of administering pirfenidone therapy
AR113839A1 (es) * 2017-11-24 2020-06-17 Pharvaris B V Antagonistas del receptor b2 de bradiquinina

Also Published As

Publication number Publication date
EP4243824B1 (en) 2025-12-24
MX2023005563A (es) 2023-09-11
WO2022101395A1 (en) 2022-05-19
ZA202305122B (en) 2024-08-28
CN116685353A (zh) 2023-09-01
CA3198246A1 (en) 2022-05-19
IL302887A (en) 2023-07-01
KR20230107269A (ko) 2023-07-14
EP4243824A1 (en) 2023-09-20
AU2021376885A1 (en) 2023-06-08
US20230338358A1 (en) 2023-10-26
JP2023549849A (ja) 2023-11-29
EP4243824C0 (en) 2025-12-24

Similar Documents

Publication Publication Date Title
ES3061585T3 (en) Prophylaxis and treatment of angioedema
CN103945849B (zh) 癌症的联合治疗
ES2968541T3 (es) Tratamiento de enfermedades cardiovasculares
US12427142B2 (en) Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl[oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid
ES3036485T3 (en) Combination comprising everolimus and amcenestrant
Giger et al. Comparison of once-versus twice-daily use of beclomethasone dipropionate aqueous nasal spray in the treatment of allergic and non-allergic chronic rhinosinusitis
EP4322941A1 (en) Combination comprising ribociclib and amcenestrant
BR112020004586A2 (pt) métodos para uso da dipivefrina
KR102766876B1 (ko) 타우로데옥시콜린산 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 코로나바이러스감염증-19(covid-19) 치료용 조성물
ES3057657T3 (en) Biphenyl sulfonamide compounds for the treatment of type iv collagen diseases
ES3026709T3 (en) Cancer treatment using docetaxel by controlling peak plasma levels
US20260091021A1 (en) Combination therapies comprising panobinostat for the treatment of cholangiocarcinoma
BR112018005771B1 (pt) Uso de um composto
HK40099091A (en) Prophylaxis and treatment of angioedema
HK40099091B (en) Prophylaxis and treatment of angioedema
RU2842683C1 (ru) Фармацевтическая комбинация осельтамивира, парацетамола, источника витамина с и блокатора гистаминовых рецепторов
CN110891574B (zh) 用于预防和/或治疗肝细胞癌的美格列明
EP4663187A1 (en) 2-hydroxy-octadecene-9-cis-oate for use in the treatment of oncological pathologies and neuropathic pain
TW202519221A (zh) Wee1抑制劑及pkmyt1抑制劑之組合
ES2688464T3 (es) Combinación de un inhibidor de la quinasa PI3 con paclitaxel para su uso en el tratamiento o la prevención de un cáncer de cabeza y cuello
NZ625611B2 (en) Combination treatment of cancer
HK1202253B (en) Combination treatment of cancer